title: Effects of induction therapy with alemtuzumab versus antithymocyte globulin among highly sensitized kidney transplant candidates.
abstract: We retrospectively compared induction therapy utilizing alemtuzumab and antithymoglobulin (ATG) in high-risk kidney transplant recipients in our center. Two hundred and fifty-one patients underwent kidney transplantation between 2009 and 2012. The high-risk patients were defined as those who had two or more times kidney transplantation and/or more than 30% panel reactive antibody. We studied 130 high-risk kidney transplant candidate; 58 (44.6%) patients received induction immunosuppressive therapy with alemtuzumab, and 72 (55.4%) with ATG. Delayed graft function developed in 11 patients receiving alemtuzumab, against the 27 patients who receiving ATG (P = 0.021). Acute cellular rejection episodes were observed in five patients in the alemtuzumab group and 19 patients in the ATG group (P = 0.009). There were three graft failures in the alemtuzumab group and eight graft failures in the ATG group due to rejection episodes. We found immunosuppressive induction therapy with alemtuzumab a significantly less incidence of acute rejection and delayed graft function than induction therapy with ATG in the high-risk kidney transplant recipients.
authors.affiliation: Shiraz Organ Transplant Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Alireza
authors.initials: A
authors.lastname: Shamsaeefar
authors.affiliation: Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Jamshid
authors.initials: J
authors.lastname: Roozbeh
authors.affiliation: Shiraz Organ Transplant Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Soraya
authors.initials: S
authors.lastname: Khajerezae
authors.affiliation: Shiraz Organ Transplant Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Saman
authors.initials: S
authors.lastname: Nikeghbalian
authors.affiliation: Shiraz Organ Transplant Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Kourosh
authors.initials: K
authors.lastname: Kazemi
authors.affiliation: Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Nasrin
authors.initials: N
authors.lastname: Motazedian
authors.affiliation: Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Bita
authors.initials: B
authors.lastname: Geramizadeh
authors.affiliation: Shiraz Organ Transplant Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Seyed Ali
authors.initials: SA
authors.lastname: Malekhosseini
mesh_terms: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum; D051799:Delayed Graft Function; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents; D016030:Kidney Transplantation
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents